Another win for Novo Nordisk

EU drug approval keeps share price soaring

Novo Nordisk announced yesterday that the European Commission has granted it marketing authorisation in all member states for its new type 2 diabetes drug Xultophy.

The news comes just over a week after the company received positive news regarding the approval process of a separate drug in the US market.

READ MORE: Thumbs up for Novo Nordisk obesity drug

New paradigm
“We believe that Xultophy represents a new paradigm with the potential to transform how type 2 diabetes is treated,” the company’s chief science officer, Mads Krogsgaard Thomsen, said in a press release.

“We look forward to making the product available to people with type 2 diabetes in Europe."

The drug was approved in Switzerland last week. Novo Nordisk wrote in the press release that Xultophy will start to be released on the European market in the first half of 2015.

The market also seems to be reacting positively to Novo’s successes. The share price of the company’s publicly traded B shares has risen from 251.7 kroner on August 18 to 281.6 kroner today.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.